clinical trial · NCT05669482
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
KRAS Activating MutationMetastatic CancerPancreas CancerNeoplasms PancreaticMalignant Neoplasm of Pancreasavutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
brief summary
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
started
Mar 22, 2023
primary completion
Aug 31, 2026
completion
Aug 31, 2027
last updated
Sep 2, 2025
detailed description
This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety, tolerability and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients previously untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC).
official title
A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol